AIMS: To determine if indirect testing for bronchial hyperresponsiveness (BHR) to monitor inhaled corticosteroid (ICS) treatment in asthma is feasible and acceptable in primary care. METHODS: Fourteen adult patients with asthma aged 22-70 years (4M:10F, forced expiratory volume in 1 s >70% predicted) taking ICS performed a test for BHR using mannitol on three visits 6 weeks apart. ICS dose adjustments were made based on the presence of BHR. The Asthma Quality of Life Questionnaire (AQLQ) and the Asthma Control Questionnaire were used at each visit. A semi structured interview at study exit assessed subject acceptability. RESULTS: BHR did not return in those with no BHR at study entry (n=9) with decreasing ICS dose. Improvements in BHR with increasing ICS dose (n=5) were observed with clinically significant improvements in AQLQ (mean score increase >0.5, p=0.02). Feasibility and acceptability of BHR testing was demonstrated. CONCLUSIONS: It is feasible and acceptable to perform BHR testing using mannitol to help identify patients with asthma who would benefit from ICS dose increases and those with no BHR who could have a dose reduction. TRIAL REGISTRATION: Australia New Zealand Clinical Trial Registry ACTRN12610000807055.
AIMS: To determine if indirect testing for bronchial hyperresponsiveness (BHR) to monitor inhaled corticosteroid (ICS) treatment in asthma is feasible and acceptable in primary care. METHODS: Fourteen adult patients with asthma aged 22-70 years (4M:10F, forced expiratory volume in 1 s >70% predicted) taking ICS performed a test for BHR using mannitol on three visits 6 weeks apart. ICS dose adjustments were made based on the presence of BHR. The Asthma Quality of Life Questionnaire (AQLQ) and the Asthma Control Questionnaire were used at each visit. A semi structured interview at study exit assessed subject acceptability. RESULTS: BHR did not return in those with no BHR at study entry (n=9) with decreasing ICS dose. Improvements in BHR with increasing ICS dose (n=5) were observed with clinically significant improvements in AQLQ (mean score increase >0.5, p=0.02). Feasibility and acceptability of BHR testing was demonstrated. CONCLUSIONS: It is feasible and acceptable to perform BHR testing using mannitol to help identify patients with asthma who would benefit from ICS dose increases and those with no BHR who could have a dose reduction. TRIAL REGISTRATION: Australia New Zealand Clinical Trial Registry ACTRN12610000807055.
Authors: J D Leuppi; C M Salome; C R Jenkins; S D Anderson; W Xuan; G B Marks; H Koskela; J D Brannan; R Freed; M Andersson; H K Chan; A J Woolcock Journal: Am J Respir Crit Care Med Date: 2001-02 Impact factor: 21.405
Authors: E F Juniper; K Svensson; P M O'Byrne; P J Barnes; C A Bauer; C G Löfdahl; D S Postma; R A Pauwels; A E Tattersfield; A Ullman Journal: Eur Respir J Date: 1999-11 Impact factor: 16.671
Authors: L Keoki Williams; Manel Pladevall; Hugo Xi; Edward L Peterson; Christine Joseph; Jennifer Elston Lafata; Dennis R Ownby; Christine C Johnson Journal: J Allergy Clin Immunol Date: 2004-12 Impact factor: 10.793
Authors: Klaus F Rabe; Mitsuru Adachi; Christopher K W Lai; Joan B Soriano; Paul A Vermeire; Kevin B Weiss; Scott T Weiss Journal: J Allergy Clin Immunol Date: 2004-07 Impact factor: 10.793
Authors: John D Brannan; Johan Bood; Ahmad Alkhabaz; David Balgoma; Joceline Otis; Ingrid Delin; Barbro Dahlén; Craig E Wheelock; Parameswaran Nair; Sven-Erik Dahlén; Paul M O'Byrne Journal: Chest Date: 2015-02 Impact factor: 9.410